3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
916
Lung Neoplasms
621
Small Cell Lung Carcinoma
170
Colorectal Neoplasms
133
Melanoma
109
Breast Neoplasms
107
Neoplasms
98
Ovarian Neoplasms
94
Neoplasm Metastasis
90
Pancreatic Neoplasms
76
Squamous Cell Carcinoma of Head and Neck
70
Stomach Neoplasms
60
Carcinoma, Renal Cell
58
Head and Neck Neoplasms
55
Esophageal Neoplasms
51
Endometrial Neoplasms
51
Triple Negative Breast Neoplasms
50
Prostatic Neoplasms
47
Uterine Cervical Neoplasms
44
Colonic Neoplasms
42
Urinary Bladder Neoplasms
41
Mesothelioma
40
Carcinoma, Hepatocellular
38
Mesothelioma, Malignant
37
Brain Neoplasms
34
Sarcoma
29
Carcinoma, Transitional Cell
29
Adenocarcinoma of Lung
28
Lung Diseases
26
Disease
26
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Thoracic
×
90 days
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA